Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern cooperative oncology group performance status (ECOG PS) score: 0-1 points~* Pathological diagnosis of oral squamous cell carcinoma (including tongue, gums, cheeks, mouth floor, hard palate, posterior molar region)~* Clinical stage of III/IVA (AJCC 2018)~* Blood routine: white blood cells \> 3,000/mm3, hemoglobin \> 8g/L, platelets \> 80,000/mm3~* Liver function: Alanine Transaminase/Aspartate Transaminase \<2.5 times the upper limit of normal, bilirubin \<1.5 times the upper limit of normal~* Renal function: serum creatinine \<1.5 times the upper limit of normal~* Sign the informed consent~Exclusion Criteria:~* There are still unresolved toxic reactions above CTCAE level 2 caused by previous anti-cancer treatment~* Grade 3-4 allergic reactions to Toripalimab, paclitaxcel or cisplatin~* Active severe clinical infection (\> CTCAE 5.0 version 2 infection)~* Difficult to control hypertension or cardiovascular disease with clinical significance (such as activity)-such as cerebrovascular accident (\< 6 months before treatment), myocardial infarction (\< 6 months before treatment), unstable angina, New York Cardiology Society (NYHA Appendix 5) congestive heart failure grade II or above, or severe arrhythmia that cannot be controlled with drugs or has potential impact on experimental treatment~* Chronic diseases requiring immunotherapy or hormone therapy~* Women during pregnancy or lactation~* Participated in other clinical studies within 30 days before enrollment~* Other circumstances that the investigator thinks are not suitable for participating in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant therapy with Toripalimab, Paclitaxcel and Cisplatin (Type: EXPERIMENTAL): Pre-operative neoadjuvant therapy will be used with the combination of immune checkpoint inhibitor of Toripalimab, and chemotherapy agents of paclitaxcel and cisplatin in patients with locally advanced OSCC. After inductive therapy, the patients will receive radical surgery and post-operative radiotherapy/chemoradiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).